|Bid||10.96 x 29200|
|Ask||10.97 x 27000|
|Day's Range||10.76 - 11.02|
|52 Week Range||9.66 - 15.60|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021|
|Forward Dividend & Yield||0.48 (4.33%)|
|Ex-Dividend Date||May 23, 2022|
|1y Target Est||16.78|
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amidst the volatility and declines on Wall Street, dividend stocks with high yields have become a prized commodity among investors. Growing fears that the economy is tipping into recession continue to draw investors into reliable stocks that offer passive income. Most dividend payers are primarily concentrated in industries that consumers rely on throughout the year, regardless of the economic environment. Such sectors typically include utilities, infrastructure, consumer staples and telecommuni
Downturns are a great time to load up on high-quality dividend stocks. Falling share prices pump up dividend yields, and that means you'll get more bang for your buck in the long run, assuming that the stocks you buy eventually return to growth. Viatris (NASDAQ: VTRS) manufactures a smorgasbord of common generic drugs and it also produces reputable brands like EpiPens, Viagra, and Lipitor.